Healthcare Industry News: colorectal cancer
News Release - November 19, 2013
Applied Proteomics Appoints Premal S. Shah As Vice President Of Business DevelopmentSAN DIEGO, Nov. 19, 2013 -- (Healthcare Sales & Marketing Network) -- Applied Proteomics Inc. (API), the leading developer of protein-based molecular diagnostics, announces the appointment of Premal S. Shah, Ph.D., as vice president of business development. Dr. Shah was previously director of business development at Genomic Health, where he was responsible for driving go-to-market strategies and establishing key collaborations with pharmaceutical companies for joint biomarker discovery ventures.
"API is focused on discovering, developing and commercializing novel diagnostic tools for precision medicine to save lives and reduce healthcare costs," said Peter Klemm, Ph.D., president and CEO of API. "Dr. Shah brings to the team important partnering and commercial experience for product development and biomarker discovery, as we advance our first diagnostic product, a blood test for precursors to colorectal cancer, and exploit our mass spectrometry discovery platform to create new diagnostics."
Also at Genomic Health, Dr. Shah was responsible for leading strategic initiatives including product development, partnerships, and mergers and acquisitions (M&As). He developed key relationships with pharmaceutical companies to conduct joint biomarker discovery programs with next-generation sequencing. Prior to that role, Dr. Shah was a management consultant at Booz & Company, advising top healthcare companies on go-to-market strategies and generating millions in previously untapped revenue streams. Dr. Shah received his Ph.D. in molecular biophysics from the California Institute of Technology.
About Applied Proteomics Inc.
Applied Proteomics Inc. (API) is advancing the application of proteomics to the development of diagnostics, companion diagnostics, and personalized medicine applications to power better medical decisions and care. API has developed a proteomics platform solution to make protein- based biomarker discovery possible as a replicable, industrial application ready to be applied to health diagnostic problems. API's platform combines improved instrumentation, faster computing and extensive genome annotations with regimented standard operating procedures, extensive quality controls, and documented processes spanning hundreds of steps from sample collection to processing through informatics. API is currently advancing several internal diagnostic development programs. API is headquartered in San Diego, CA. For more information, please visit http://www.appliedproteomics.com.
Source: Applied Proteomics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.